Understanding immune signals that drive pancreatic cancer growth
Project 2: Immune signals promoting pancreas cancer stemness and progression
['FUNDING_P01'] · STANFORD UNIVERSITY · NIH-10927300
This study is looking at how immune cells and cancer cells work together in pancreatic cancer to understand what helps the cancer grow and come back, with the goal of finding new ways to improve treatment for patients.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-10927300 on ClinicalTrials.gov |
What this research studies
This research investigates how immune cells interact with cancer cells and surrounding tissues in pancreatic ductal adenocarcinoma (PDAC), a particularly aggressive form of cancer. The team aims to uncover the mechanisms by which these interactions promote cancer development and recurrence, focusing on specific signaling pathways like IL-22 and its receptor IL-22RA1. By studying these immune signals, the researchers hope to identify new therapeutic targets that could improve treatment outcomes for patients with PDAC.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma, particularly those exhibiting high levels of IL-22RA1 expression.
Not a fit: Patients with other types of cancer or those without pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective therapies for pancreatic cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results in targeting immune signaling pathways in cancer treatment, suggesting that this approach may yield significant advancements.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ARTANDI, STEVEN E — STANFORD UNIVERSITY
- Study coordinator: ARTANDI, STEVEN E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Induction, Cancers